GPR43 has been implicated in the regulation of fatty-acid and glucose homeostasis in adipose tissue and the intestine and may thus have potential therapeutic relevance in the treatment of type 2 diabetes, insulin resistance and obesity. This evidence concerns the gene FFAR2 and obesity due to melanocortin 4 receptor deficiency.